After 13% discount Innate Pharma raises $69M; AZTherapies bags $26.3M from Series C financing round
→ AstraZeneca-partnered French biotech Innate Pharma — which was shooting for a $100 million IPO by offering 10.7 millions shares at $7.50 per share last month — has raised $69 million in the US by offering 12.5 million shares at $5.50 (€4.97), a 13% discount to its prior closing price on Euronext Paris (€5.71; ticker $IPH). Citi, SVB Leerink and Evercore ISI were the lead managers. The company plans to list on the Nasdaq under the symbol $IPHA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.